5413results about How to "Reduce degradation" patented technology

A conversational computing system that provides a universal coordinated multi-modal conversational user interface (CUI) (10) across a plurality of conversationally aware applications (11) (i.e., applications that “speak” conversational protocols) and conventional applications (12). The conversationally aware maps, applications (11) communicate with a conversational kernel (14) via conversational application APIs (13). The conversational kernel (14) controls the dialog across applications and devices (local and networked) on the basis of their registered conversational capabilities and requirements and provides a unified conversational user interface and conversational services and behaviors. The conversational computing system may be built on top of a conventional operating system and APIs (15) and conventional device hardware (16). The conversational kernel (14) handles all I/O processing and controls conversational engines (18). The conversational kernel (14) converts voice requests into queries and converts outputs and results into spoken messages using conversational engines (18) and conversational arguments (17). The conversational application API (13) conveys all the information for the conversational kernel (14) to transform queries into application calls and conversely convert output into speech, appropriately sorted before being provided to the user.

Provided are novel methods of filling gaps with a flowable dielectric material. According to various embodiments, the methods involve performing a surface treatment on the gap to enhance subsequent bottom up fill of the gap. In certain embodiments, the treatment involves exposing the surface to activated species, such as activated species of one or more of nitrogen, oxygen, and hydrogen. In certain embodiments, the treatment involves exposing the surface to a plasma generated from a mixture of nitrogen and oxygen. The treatment may enable uniform nucleation of the flowable dielectric film, reduce nucleation delay, increase deposition rate and enhance feature-to-feature fill height uniformity.

A system stores criteria specified by a funder relating to trade transactions for buyers and sellers. The system compares the criteria with a proposed purchase order to determine whether the system can generate a payment guarantee on behalf of the funder for the buyer to the seller. The system also compares subsequent documents relating to an original purchase order with the original purchase order to ensure that the terms of the purchase order are properly fulfilled. When the appropriate conditions for payment are met, the system issues a funds transfer instruction to transfer payment from the buyer to the seller.

This invention provides a network management equipment and a packet switching equipment which eliminate a connection setup delay time, reduce a delay and a delay variation involved in data transfer, and effectively perform connectionless data flow processing in a large data network. The network is divided into a connection-oriented core network and a plurality of connectionless access networks connected to the core network where a plurality of connections (called permanent virtual route (PVR)) are set up among a plurality of edge nodes. The network management equipment selects one route from a plurality of PVRs for connectionless data flow received from one of the access networks and transfers data along the PVR.

The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.

Methods and apparatuses for circuit design to reduce power usage, such as reducing temperature dependent power usage, and/or to improve timing, such as reducing temperature dependent delay or transition time. At least one embodiment of the present invention reduces the power dissipation and improves the timing of an integrated circuit to optimize the design. A thermal analysis is used to determine the temperature dependent power dissipation of a circuit and the temperature distribution of the circuit resulting from dissipating the heat created by the temperature dependent power dissipation. Then, the components of the design are selectively transformed to reduce the power dissipation and to improve timing based on the temperature solution. The transformation may include placement changes and netlist changes, such as the change of transistor threshold voltages for cells or for blocks of the circuit chip.

MEMS packaging schemes having a system-on-package (SOP) configuration and a system-on-board (SOB) configuration are provided. The MEMS package comprises one or more MEMS dies, a cap section having one or more integrated circuit (IC) dies, and a packaging substrate or a printed circuit board (PCB) arranged in a stacking manner. Vertical connectors, such as through-silicon-vias (TSVs), are formed to provide short electrical connections between the various components. The MEMS packaging schemes enable higher integration density, reduced MEMS package footprints, reduced RC delays and power consumption.

The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and/or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention.

The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cosmetically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease).

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations as well as other therapeutic agents may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices. In each of these instances, antioxidants are utilized to prolong product integrity.

A lighting device comprises a solid state light emitter, first and second electrodes connected to the emitter, an encapsulant region comprising a silicone compound and a supporting region. The encapsulant region extends to an external surface of the lighting device. At least a portion of the first electrode is surrounded by the supporting region. The encapsulant region and the supporting region together define an outer surface which substantially encompasses the emitter. A method of making a lighting device, comprises electrically connecting first and second electrodes to an emitter; inserting the emitter into mold cavity; inserting an encapsulant composition comprising a one silicone compound; and then inserting a second composition to substantially surround at least a portion of the first electrode.

Techniques for transmitting voice/data and packet data services such that packet data transmissions have less impact on voice/data transmissions. In one aspect, voice/data and packet data can be multiplexed within a transmission interval such that the available resources are efficiently utilized. In another aspect, the amount of variation in the total transmit power from a base station is controlled to reduce degradation to transmissions from this and other base stations. In a specific method for concurrently transmitting a number of types of data, a first data type (e.g., voice, overhead, and some data) and a second data type are respectively processed in accordance with first and second signal processing schemes to generate first and second payloads, respectively. First and second partitions are then defined in a transmission interval. The first and second payloads are time multiplexed into the first and second partitions, respectively, and the multiplexed payloads are transmitted.

In certain implementations, intent prediction is provided for a natural language utterance based on a portion of the natural language utterance prior to a system detection of an end of the natural language utterance. In some implementations, a first portion of a natural language utterance of a user may be received. Speech recognition may be performed on the first portion of the natural language utterance to recognize one or more words of the first portion of the natural language utterance. Context information for the natural language utterance may be obtained. Prior to a detection of an end of the natural language utterance, a first intent may be predicted based on the one or more words of the first portion and the context information. One or more user requests may be determined based on the first predicted intent.

Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.

A high resolution 2D-3D switchable autostereoscopic display apparatus includes: a backlight unit emitting light; a polarizer sheet changing the light emitted from the backlight unit so that the light has only a specific polarization direction; a polarization switch converting the direction of the polarization of incident light; a birefringent element array comprising a plurality of alternating first and second birefringent elements and changing the polarization direction of incident light so that the polarization of light transmitted by the first birefringent elements is perpendicular to the polarization of light transmitted by the second birefringent elements; a lenticular lens sheet separating and emitting incident light to a first eye viewing zone and a second eye viewing zone; and a display panel displaying an image.

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

An organic light emitting display including a scan signal line forwarding a scan signal, a data line sending a data signal and a pixel coupled to the scan signal line and the data line, the organic light emitting diode display, wherein the pixel includes a first switching transistor transmitting a data signal from the data line in response to the scan signal of the scan signal line, a driving transistor, coupled to the first switching transistor, controlling driving current from a first power source line, a storage capacitor coupled between the driving transistor and the first power source line, an organic light emitting diode, coupled between the driving transistor and a second power source line, displaying an image with the driving current controlled by the driving transistor, an initial switching transistor, coupled between the storage capacitor and an initial power source line, initializing the storage capacitor, and a switching transistor for applying a reverse bias, coupled between the second power source line and the initial power source line, applying a reverse bias voltage to the organic light emitting diode.